| Literature DB >> 33117026 |
Marcella Nebbioso1, Antonietta Moramarco1, Alessandro Lambiase1, Sandra Giustini2, Marco Marenco1, Emanuele Miraglia2, Pasquale Fino2, Chiara Iacovino2, Ludovico Alisi1.
Abstract
INTRODUCTION: Neurofibromatosis type 1 (NF1) is a multisystemic disease caused by the mutation of Nf1 gene located on chromosome 17q11.2. The mutation determines the loss of function of the protein neurofibromin with consequent uncontrolled cellular proliferation. Patients are characterized by a wide range of dermatological, neurological, and ophthalmological symptoms.Entities:
Keywords: FDT; electrophysiologic testing; frequency doubling technology Matrix perimetry; neurofibromatosis type 1; optic glioma; pattern visual evoked potentials
Year: 2020 PMID: 33117026 PMCID: PMC7585783 DOI: 10.2147/EB.S255184
Source DB: PubMed Journal: Eye Brain ISSN: 1179-2744
Figure 1Neurofibromatosis type 1 (NF1) patient. Pattern visual evoked potentials (p-VEPs): Latency (increased) and amplitude (reduced) values of the P100 waves, obtained for each spatial stimulation frequency (120ʹ, 60ʹ, and 15ʹ).
Pattern Visual Evoked Potentials (pVEPs) Amplitude (Amp in Micronvolts = μV) and Latency (Lat in Milliseconds = ms) Results in Both Studied Groups, Neurofibromatosis Type 1 (NF1) Patients and Healthy Subjects
| pPEV Exam | NF1 | Controls | |||||
|---|---|---|---|---|---|---|---|
| Mean | Sd | Median | Mean | Sd | Median | ||
| pPEV 120 lat | 117.6 | 18.5 | 111 | 106.2 | 5.8 | 107 | |
| pPEV 120 amp | 9.8 | 5.2 | 10.2 | 14.6 | 5.5 | 13.9 | |
| pPEV 60 lat | 115.4 | 18.0 | 108 | 105.5 | 4.5 | 105.5 | |
| pPEV 60 amp | 9.9 | 5.2 | 10.2 | 16.2 | 5.8 | 15 | |
| pPEV 15 lat | 119.7 | 13.0 | 115 | 113.1 | 6.9 | 112 | |
| pPEV 15 amp | 10.9 | 5.0 | 10.5 | 16.7 | 6.5 | 17.0 | |
Notes: Statistically significant results are in bold. p: parametric. 120ʹ, 60ʹ,15ʹ: low, medium and high spatial frequencies, respectively.
Abbreviation: Sd, standard deviation.
Results of the Visual Field Carried Out by Means of a Computerized Frequency Doubling Technology (FDT) Matrix Perimetry in Both Studied Groups, Neurofibromatosis Type 1 (NF1) Patients and Healthy Controls
| NF1 | Controls | |||||
|---|---|---|---|---|---|---|
| Number of Subjects | % | Number of Subjects | % | 0.0004 | ||
| GHT | Normal | 19 | 36,5 | 27 | 79.4 | |
| Borderline | 6 | 11,5 | 2 | 5.9 | ||
| Outside | 27 | 52,0 | 5 | 14.7 | ||
| NF1 | Controls | |||||
| Mean | Sd | Mean | Sd | |||
| CS | 27.6 | 5.2 | 31.6 | 3.1 | ||
| MD | −3.8 | 4.0 | 0.6 | 1.8 | ||
| PSD | 4.3 | 1.4 | 2.8 | 0.5 | ||
Note: Statistically significant results in bold.
Abbreviations: GHT, glaucoma hemifield test; CS, central sensitivity (in dB); MD, mean deviation (in dB); PSD, pattern standard deviation (in dB); Sd, standard deviation.
Figure 2Altered perimetry, performed with frequency doubling technology (FDT) Matrix.